Cancer Immunology Research,
Год журнала:
2018,
Номер
6(9), С. 990 - 1000
Опубликована: Сен. 1, 2018
Immunotherapies
such
as
checkpoint-blocking
antibodies
and
adoptive
cell
transfer
are
emerging
treatments
for
a
growing
number
of
cancers.
Despite
clinical
activity
immunotherapies
across
range
cancer
types,
the
majority
patients
fail
to
respond
these
resistance
mechanisms
remain
incompletely
defined.
Responses
immunotherapy
preferentially
occur
in
tumors
with
preexisting
antitumor
T-cell
response
that
can
most
robustly
be
measured
via
expression
dendritic
CD8
Annals of Oncology,
Год журнала:
2018,
Номер
30(1), С. 44 - 56
Опубликована: Ноя. 1, 2018
Treatment
with
immune
checkpoint
blockade
(ICB)
agents
such
as
anti-programmed
cell
death
protein
1
(PD-1),
death-ligand
(PD-L1),
and/or
anti-cytotoxic
T-lymphocyte-associated
4
(CTLA-4)
can
result
in
impressive
response
rates
and
durable
disease
remission
but
only
a
subset
of
patients
cancer.
Expression
PD-L1
has
demonstrated
utility
selecting
for
to
ICB
proven
be
an
important
biomarker
patient
selection.
Tumor
mutation
burden
(TMB)
is
emerging
potential
biomarker.
However,
refinement
interpretation
contextualization
required.
Genes & Development,
Год журнала:
2018,
Номер
32(19-20), С. 1267 - 1284
Опубликована: Окт. 1, 2018
The
presence
of
inflammatory
immune
cells
in
human
tumors
raises
a
fundamental
question
oncology:
How
do
cancer
avoid
the
destruction
by
attack?
In
principle,
tumor
development
can
be
controlled
cytotoxic
innate
and
adaptive
cells;
however,
as
develops
from
neoplastic
tissue
to
clinically
detectable
tumors,
evolve
different
mechanisms
that
mimic
peripheral
tolerance
order
tumoricidal
attack.
Here,
we
provide
an
update
recent
accomplishments,
unifying
concepts,
future
challenges
study
tumor-associated
cells,
with
emphasis
on
metastatic
carcinomas.
